Saturday 17 October 2026
Export NBIX’s income statement to Excel — free account
Neurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
135.71
1.24
−0.91%
Follow NBIX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 3 | 6 | 7 | 5 | 4 | 6 | 6 | 8 | 7 |
P/E ratio |
0.00 | 0.00 | 324.59 | 268.73 | 21.98 | 89.65 | 74.58 | 51.86 | 40.38 | 29.43 |
P/S ratio |
92.53 | 39.55 | 14.28 | 12.49 | 8.53 | 7.11 | 7.73 | 6.82 | 5.82 | 4.93 |
Altman Z-Score |
35.68 | 7.56 | 7.24 | 8.65 | 9.70 | 7.62 | 11.59 | 8.70 | 8.83 | 7.80 |
Altman Z″-Score (non-manufacturers) |
(0.53) | (0.97) | 1.66 | (0.12) | 4.35 | 3.70 | 5.40 | 4.58 | 5.61 | 6.21 |
P/FCF ratio |
0.00 | 0.00 | 84.09 | 74.42 | 41.01 | 34.56 | 35.63 | 35.59 | 24.60 | 18.85 |
Beneish M-Score |
— | — | (1.52) | (1.75) | (1.55) | (2.60) | (2.15) | (1.68) | (2.23) | (2.64) |
P/Operating CF |
(106.00) | 172.16 | 127.57 | 100.99 | 94.43 | 1,918.35 | 80.45 | 104.21 | 56.51 | 36.33 |
P/B ratio |
10.65 | 18.77 | 13.40 | 15.46 | 7.92 | 5.86 | 6.74 | 5.77 | 5.29 | 4.34 |
Price to Tangible BV |
10.65 | 18.77 | 13.40 | 15.46 | 7.92 | 5.86 | 6.89 | 5.86 | 5.37 | 4.35 |
EV/Sales |
84.07 | 38.72 | 14.54 | 12.24 | 8.44 | 7.11 | 7.38 | 6.57 | 5.60 | 4.61 |
EV/EBITDA |
0.00 | 0.00 | 109.92 | 96.46 | 45.72 | 58.40 | 40.97 | 48.80 | 23.07 | 20.71 |
EV/Operating CF |
(28.69) | (72.50) | 64.72 | 65.62 | 38.62 | 31.44 | 32.39 | 31.78 | 22.14 | 16.85 |
EV/FCF |
(27.62) | (67.54) | 85.67 | 72.91 | 40.55 | 34.60 | 34.04 | 34.27 | 23.66 | 17.61 |
Quick Ratio |
10.11 | 10.05 | 8.03 | 1.41 | 5.14 | 3.65 | 2.49 | 2.25 | 3.06 | 2.92 |
Current Ratio |
10.21 | 10.20 | 8.36 | 1.47 | 5.45 | 3.96 | 2.70 | 2.45 | 3.40 | 3.39 |
Net Debt/EBITDA |
2.15 | 1.27 | (4.40) | (5.83) | (2.50) | (2.72) | (3.69) | (4.06) | (1.88) | (2.33) |
Debt/Assets |
0.17% | 45.21% | 39.12% | 6.66% | 18.33% | 16.17% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.99 | 0.81 | 0.14 | 0.28 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.27 | 0.50 | 0.69 | 0.69 | 0.60 | 0.67 | 0.67 | 0.68 | 0.69 |
Operating CF/Net income |
0.75 | 0.66 | 4.81 | 3.97 | 0.56 | 2.86 | 2.20 | 1.56 | 1.74 | 1.64 |
Capex/Depreciation |
(0.82) | (0.43) | (1.08) | (0.53) | (0.36) | (0.66) | (0.85) | (9.43) | (42.44) | (1.95) |
Interest Coverage |
(49.12) | (6.73) | 1.21 | 2.26 | 4.97 | 3.97 | 35.07 | 54.54 | — | — |
| (38.17%) | (41.50%) | 4.95% | 6.62% | 46.20% | 7.17% | 10.03% | 12.68% | 14.16% | 16.38% | |
| (33.60%) | (24.10%) | 2.33% | 3.22% | 26.79% | 4.71% | 6.96% | 8.89% | 9.79% | 11.46% | |
ROIC |
(1,130.99%) | (36.36%) | 10.53% | 84.62% | 15.84% | 6.42% | 21.66% | 13.06% | 23.56% | 21.83% |
Return on Tangible Assets |
(49.28%) | (27.88%) | 3.09% | 12.03% | 46.59% | 11.41% | 15.86% | 24.41% | 26.26% | 25.61% |
Average Days of Receivables |
0.00 | 70.29 | 46.44 | 58.63 | 54.83 | 59.73 | 85.81 | 84.97 | 74.25 | 87.64 |
Research and Development Expense of Revenue |
628.61% | 56.81% | 34.53% | 25.38% | 26.29% | 28.95% | 31.15% | 29.94% | 31.04% | 35.51% |
Selling, General and Administrative Expense of Revenue |
453.87% | 105.12% | 55.16% | 44.93% | 41.43% | 51.46% | 50.56% | 47.04% | 42.76% | 40.42% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
189.76% | 26.31% | 12.88% | 9.55% | 9.56% | 11.84% | 11.63% | 10.30% | 8.30% | 7.62% |
Graham Net Nets |
0.08 | 0.02 | 0.04 | 0.02 | 0.05 | 0.03 | 0.07 | 0.05 | 0.04 | 0.08 |
Graham Number |
0.00 | 0.00 | 5.14 | 7.91 | 34.45 | 17.62 | 25.41 | 36.13 | 44.29 | 59.55 |
Earnings Yield |
(4.19%) | (2.06%) | 0.31% | 0.37% | 4.55% | 1.12% | 1.34% | 1.93% | 2.48% | 3.40% |
Free Cash Flow Yield |
(3.29%) | (1.45%) | 1.19% | 1.34% | 2.44% | 2.89% | 2.81% | 2.81% | 4.07% | 5.31% |
Revenue per Share |
0.17 | 1.83 | 5.00 | 8.60 | 11.23 | 11.98 | 15.54 | 19.32 | 23.46 | 28.75 |
Operating CF per Share |
(1.22) | (1.07) | 1.12 | 1.60 | 2.45 | 2.71 | 3.54 | 3.99 | 5.93 | 7.87 |
Capex per Share |
(0.05) | (0.08) | (0.27) | (0.16) | (0.12) | (0.25) | (0.17) | (0.29) | (0.38) | (0.34) |
Free Cash Flow per Share |
(1.27) | (1.15) | 0.85 | 1.44 | 2.34 | 2.46 | 3.37 | 3.70 | 5.55 | 7.52 |
Cash per Share |
3.54 | 5.86 | 7.22 | 7.32 | 8.60 | 7.52 | 10.33 | 10.56 | 10.72 | 14.88 |
Shareholders Equity per Share |
3.63 | 4.22 | 5.33 | 6.95 | 12.10 | 14.52 | 17.83 | 22.85 | 25.79 | 32.69 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.63 | 4.22 | 5.33 | 6.95 | 12.10 | 14.52 | 17.83 | 22.85 | 25.79 | 32.69 |
Free Cash Flow |
(110.28) | (101.26) | 76.60 | 132.30 | 217.60 | 233.10 | 322.90 | 361.60 | 557.20 | 748.70 |
Working Capital |
280.03 | 500.49 | 649.54 | 265.70 | 829.70 | 727.00 | 915.80 | 952.20 | 1,217.00 | 1,779.30 |
Capital Expenditures |
(4.09) | (6.93) | (24.80) | (14.70) | (10.90) | (23.40) | (16.50) | (28.30) | (38.20) | (34.00) |
Net Current Asset Value |
260.23 | 109.47 | 225.39 | 161.90 | 407.70 | 274.30 | 792.60 | 587.60 | 595.70 | 1,144.30 |
EV/EBIT |
0.00 | 0.00 | 178.33 | 133.42 | 54.14 | 78.68 | 44.14 | 49.39 | 23.11 | 21.30 |
Capex to Sales |
0.27 | 0.04 | 0.06 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 175.03 | 136.18 | 54.75 | 78.61 | 46.20 | 51.30 | 24.02 | 22.79 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.79 | 1.47 | 0.68 | 0.66 | 0.67 | 0.61 | 0.33 | 0.04 | 0.01 | 0.19 |
Cash ROIC |
(17.71%) | (8.05%) | 5.04% | 9.49% | 9.69% | 9.63% | 11.97% | 11.08% | 15.20% | 15.82% |
Accounts Receivable Turnover |
0.00 | 7.15 | 10.19 | 8.57 | 7.37 | 6.62 | 5.56 | 4.78 | 5.13 | 4.91 |
Accounts Payable Turnover |
0.00 | 0.03 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.10 | 0.07 | 0.09 |
Inventory Turnover |
— | 0.21 | 0.82 | 0.53 | 0.45 | 0.49 | 0.71 | 1.08 | 0.71 | 0.82 |
Average Days of Payables |
0.00 | 15,577.99 | 6,434.21 | 6,969.53 | 6,096.58 | 5,763.43 | 5,468.71 | 4,126.25 | 4,955.41 | 4,723.98 |
Days of Inventory on Hand |
— | 298.05 | 809.26 | 853.31 | 1,011.88 | 778.50 | 552.22 | 352.13 | 616.21 | 483.40 |
Average Receivables |
— | 22.61 | 44.27 | 92.00 | 141.85 | 171.30 | 267.75 | 394.65 | 459.20 | 582.95 |
Average Payables |
14.37 | 39.85 | 69.95 | 113.84 | 155.00 | 197.25 | 286.70 | 398.20 | 455.20 | 567.95 |
Average Inventory |
— | 6.01 | 5.94 | 14.08 | 22.65 | 29.25 | 32.80 | 36.70 | 47.85 | 63.20 |
Average Assets |
419.94 | 591.34 | 905.37 | 1,149.58 | 1,520.35 | 1,903.60 | 2,220.60 | 2,810.05 | 3,485.05 | 4,175.10 |
Average Common Equity |
369.67 | 343.51 | 426.45 | 558.83 | 881.55 | 1,250.10 | 1,540.90 | 1,969.90 | 2,410.85 | 2,921.40 |
Columns are period end dates